Therapeutic antibodies

Question 1

Alemtuzumab

Answer 1

Target CD52

For CLL and MS

Question 2

Bevacizumab

Answer 2

Target VEGF

For CRC, RCC, non-small cell lung ca.

Question 3

Cetuximab

Answer 3

Target EGFR

Stage IV CRC, head and neck cancer

Question 4

Rituximab

Answer 4

Target CD20

B-cell NHL, CLL, RA, ITP

Question 5

Trastuzumab

Answer 5

Targer HER2/neu

Breast cancer, gastric cancer

Question 6

Adalimumab, certrolizumab, golimumab, infliximab

Answer 6

Targets soluble TNF-alpha

IBD, RA, ankylosing spondylitis, psoriasis

Question 7

Daclizumab

Answer 7

Target CD25

relapsing MS

Question 8

Eculizumab

Answer 8

Targers C5

PNH

Question 9

Natalizumab

Answer 9

alpha-4 integrin (WBC adhesion) risk of PML in JC virus

MS, CD

Question 10

Ustekizumab

Answer 10

IL-12/IL-23

Psoriasis/PsA

Question 11

Abciximab

Answer 11

Platelet GPIIB/IIIa

Antiplatelet for preventing ischemic complications in PCI

Question 12

Denosumab

Answer 12

RANKL

Osteoporosis, mimics OPG, acts to inhibit clasts

Question 13

Digoxin immune Fab

Answer 13

Antidote for digoxin toxicity

Question 14

Omalizumab

Answer 14

IgE

Refractory allergic asthma; prevents IgE binding to FceRI

Question 15

Palivizumab

Answer 15

RSV F protein

RSV prophylaxis in at risk kids

Question 16

Ranibizumab

Answer 16

VEGF

Neovascular age-related macular degen., proliferative diabetic retinopathy, macular edema

Question 17

Bevacizumab

Answer 17

VEGF

Neovascular age-related macular degen., proliferative diabetic retinopathy, macular edema